Expert Rev Proteomics. 2008;5(2):249-262. Similar to the potential ALS biomarkers reported in serum and plasma, many of the CSF-based studies utilize small subject numbers within the sample groups ...

Clene will soon meet with the Food and Drug Administration to discuss analyses that could support an application for ...

while correctly ruling out ALS in over 80% of non-ALS cases. The other biomarkers performed poorly, with accuracy rates ...

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, ...

Precision Care Medicine students work with clinical faculty at Johns Hopkins Medicine to learn how to use machine learning ...

ALS (also known as Motor Neuron Disease (MND)) affects around 45,000 people in Europe at any one time. It attacks the nerves ...

“We are thrilled to be the first company to evaluate multiple digital clinical biomarker endpoints in an ALS therapeutic trial to gauge short-term disease progression across key functional ...

Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose ...